ストックスクリーナーアプリを入手
3.12
0.32%
-0.010
プレマーケット:
3.14
0.02
+0.64%
前日終値:
$3.13
開ける：
$3.03
24時間の取引高:
684.36K
Relative Volume:
0.20
時価総額：
$298.58M
収益：
-
当期純損益:
$-84.23M
株価収益率:
-3.3777
EPS:
-0.9237
ネットキャッシュフロー:
$-77.15M
1週間 パフォーマンス:
-4.00%
1か月 パフォーマンス:
-0.64%
6か月 パフォーマンス:
-66.05%
1年 パフォーマンス:
+3.31%
1日の値動き範囲:
$2.99
$3.20
1週間の範囲:
$2.79
$3.36
52週間の値動き範囲:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
名前
Rezolute Inc
セクター
電話
650-206-4507
住所
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.12 | 298.58M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-25 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-12-11 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | ダウングレード | Craig Hallum | Buy → Hold |
| 2025-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-08-27 | 開始されました | Guggenheim | Buy |
| 2024-07-17 | 開始されました | BTIG Research | Buy |
| 2024-06-04 | 開始されました | Craig Hallum | Buy |
| 2024-04-09 | 開始されました | Maxim Group | Buy |
| 2022-08-02 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 開始されました | ROTH Capital | Buy |
| 2021-05-27 | 開始されました | Oppenheimer | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Rezolute Inc (RZLT) 最新ニュース
RZLT.O PE Ratio & Valuation, Is RZLT.O Overvalued - Intellectia AI
Rezolute stock gains after FDA meeting on Ersodetug program update - MSN
Rezolute, Inc. (RZLT) stock price, news, quote and history - Yahoo Finance UK
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
What is HC Wainwright's Estimate for Rezolute Q1 Earnings? - MarketBeat
Rezolute CFO Evans Daron buys $28,500 in RZLT stock By Investing.com - Investing.com India
Rezolute CFO Evans Daron buys $28,500 in RZLT stock - Investing.com
Rezolute (RZLT) CFO adds 10,000 shares in open-market purchase - stocktitan.net
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart - Capital.com
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug (NASDAQ:RZLT) - Seeking Alpha
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Will Rezolute Inc outperform during market ralliesTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Opaleye Management Inc.'s Rezolute Inc(RZLT) Holding History - GuruFocus
Volume Report: Will Rezolute Inc stock go up in YEAR2026 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT) - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - GuruFocus
Cantor Fitzgerald Maintains Rezolute(RZLT.US) With Hold Rating - Moomoo
Rezolute Shares Rise After FDA Signals Hope for Treatment Approval - timothysykes.com
Rezolute Shares Rise Following FDA Discussion Regarding Ersodetug Program Progress - Bitget
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update - The Globe and Mail
Rezolute’s Shares Soar Despite Initial Obstacles in Trial Data - StocksToTrade
Wedbush upgrades Rezolute stock rating on FDA feedback By Investing.com - Investing.com Australia
Citizens reiterates Market Perform on Rezolute stock after FDA update By Investing.com - Investing.com India
RZLT: Wedbush Upgrades Rezolute with Raised Price Target | RZLT Stock News - GuruFocus
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush - marketbeat.com
Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting - Investing.com
Rezolute stock maintained at Buy by H.C. Wainwright after FDA meeting - Investing.com Canada
Wedbush upgrades Rezolute stock rating on FDA feedback - Investing.com
Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2 - marketscreener.com
Citizens reiterates Market Perform on Rezolute stock after FDA update - Investing.com
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question - sahmcapital.com
Energy Moves: Is Rezolute Inc a top pick in the sectorMarket Movement Recap & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update - Investing.com India
BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update By Investing.com - Investing.com South Africa
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - biospace.com
Rezolute Updates on Congenital Hyperinsulinism Program After FDA Meeting; SunRIZE Data Under Review for Potential Advancement 1 - Minichart
Rezolute (RZLT) Shares Surge After Positive FDA Meeting - GuruFocus
Rezolute gains after positive FDA meeting (RZLT:NASDAQ) - Seeking Alpha
Rezolute to submit sunRIZE trial data to FDA for review By Investing.com - Investing.com Canada
Rezolute (RZLT) Discusses sunRIZE Study Results with FDA - GuruFocus
Rezolute Prepares FDA Submission After sunRIZE Trial Review - tipranks.com
Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint - marketscreener.com
Rezolute says FDA invited submission of sunRIZE data after Type B meeting; review could inform marketing path - TradingView
Rezolute to submit sunRIZE trial data to FDA for review - Investing.com
Rezolute (RZLT) gets FDA review track for congenital hyperinsulinism trial - Stock Titan
Rezolute Inc (RZLT) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):